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Introduction
DNA methylation is a powerful mechanism for the suppression of gene activity.
The reciprocal relationship between the density of methylated cytosine residues and the transcriptional activity of a gene has been widely documented. [1] Gene hypermethylation, especially, is associated with the silencing of tumor suppressor genes in cancer and, therefore, many kinds of cancer are acquired by aberrant methylation of the CpG islands within promoter regions of gene loci. [2] Thus, DNA methylation is largely involved in the tumorigenesis of many kinds of cancer.
Chronic inflammation is also tightly associated with high levels of DNA methylation. Kanai et al. reported that DNA methylation alterations were involved in inflammation due to chronic hepatitis or liver cirrhosis resulting from infection with hepatitis B or C virus. [3] In patients with rheumatoid arthritis, CpG islands in the DR3 gene promoter were specifically methylated to down-modulate the expression of DR3 protein in rheumatoid synovial cells [4] . In the field of gastrointestinal tract, the correlation between methylation of gastric mucosa and inflammation caused by
Helicobacter pylori (H. pylori) infection has particularly been highlighted. H. pylori
infection potently induces aberrant DNA methylation in gastric mucosa, and methylation levels of a unique set of individual markers in gastric mucosa decreased after H. pylori eradication. [5] Ulcerative colitis (UC) is a relapsing non-transmural inflammatory disease that is restricted to the colon, with unknown etiology. [6] UC is characterized by mucosal ulceration, rectal bleeding, diarrhea, and abdominal pain. Also in UC, involvement of DNA methylation of colonic mucosa has been suggested. For example, it has been shown that the methylation level of the estrogen receptor 1 (ESR1) gene, which is known as an age-related methylation locus, [7] in nonneoplastic colorectal epithelium was higher in UC patients with neoplasia than in UC patients without neoplasia. [8] In addition, previous reports indicated that methylation of E-cadherin (CDH1) or hyperplastic polyposis protein 1 (HPP1) in colon mucosa of UC was an early event in UC-associated carcinogenesis. [9, 10] However, the majority of published reports correlate methylation of colonic mucosa with the occurrence of UC-related dysplasia or cancer without considering the inflammatory status of colonic mucosa. Chronic active inflammation is largely correlated with the occurrence of dysplasia or cancer in the field of UC as well as H.pylori associated gastritis. [5, 11] In this context, active inflammation in UC may be correlated with accumulation of methylation, resulting in susceptibility to carcinogenesis, as shown in gastric carcinogenesis correlated with H.pylori-induced methylation.
In this study, therefore, we investigated the methylation status of colon mucosa from UC patients who underwent colectomy, and correlated it with mucosal inflammatory status. The aim of this study was to verify whether DNA methylation that is specific to mucosal inflammation also occurs in the colonic mucosa of UC. Colorectal mucosal samples were collected from active inflamed mucosa in the distal portion (mainly sigmoid colon), and quiescent mucosa in the proximal portion (mainly ascending colon) of each patient. When available, samples from active mucosa in the proximal portion were also collected. In addition, peripheral blood buffy coat was collected from 15 of the 28 UC patients. These samples were stored at −80°C until analysis.
Clinical information about patients was obtained, including age, gender, disease duration, classification of disease as steroid-dependence or -refractory, and total amount of corticosteroids used. This study protocol was approved by the institutional review board of Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. All patients provided their informed consent.
Methylation analysis
The DNA in colonic tissue and peripheral blood buffy coat was extracted using the QIAamp DNA mini kit according to the manufacturer's protocol (Qiagen, Valencia, CA). Genomic DNA was modified by sodium bisulfite to convert unmethylated cytosines to uracil using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer's protocol. The methylation status of bisulfite-converted DNA was determined by MethyLight, a fluorescence-based, real-time polymerase chain reaction (PCR) assay as described previously. [12] [13] [14] [15] [16] [17] The CpG loci examined were the promoter regions of glycoprotein/ATP binding CCTCTACATACGCCGCGAAT). [12, [15] [16] [17] [18] The primer and probe sequences for the other 9 regions were described previously. [16] The specificity of the reactions for methylated DNA was confirmed separately using SssI-treated genomic DNA as the methylated control.
For data presentation, the percentage of methylated references (PMR) was indicated. PMR at a specific locus was calculated by dividing the GENE:ACTB ratio of a sample by that of SssI-treated genomic DNA and multiplying by 100. 
Statistical analysis
The differences in CpG island methylation levels (the PMR of ABCB1, CDH1, ESR1, HPP1, MYOD1, or GDNF) between proximal colon and distal colon mucosa of each UC patient was evaluated using the Wilcoxon signed-ranks test. The differences in methylation levels between quiescent and active colon mucosa of patients with UC was evaluated using the Mann-Whitney's U test. The association between PMR and clinical characteristics was evaluated using multiple linear regression analysis. These analyses were carried out using SAS version 9.1 (SAS Institute, Cary, NC, USA). All P-values were two-tailed and considered significant when less than 0.05.
Results

Clinical characteristics of patients
The methylation status of 28 UC patients who underwent colectomy was examined. Of these, 21 patients had active inflamed mucosa in the distal colon and quiescent mucosa in the proximal colon, and 13 patients had active inflamed mucosa both in the distal and proximal colon. All patients had active inflamed mucosa in the distal colon, and 6 patients had both active and quiescent portions in the proximal colon.
Clinical characteristics of these patients are shown in Table 1 .
Methylation status of colonic mucosa in each UC patient
To examine the methylation levels of colonic mucosa in UC patients according to 
Specific methylation for active inflammation of UC
To identify specific methylation for active inflammation of UC, the methylation status of all samples was stratified according to mucosal inflammatory status. The methylation status of active inflamed colonic mucosal samples (41 samples) was compared with that of quiescent mucosal samples (21 samples) from all 28 patients (Figure 3 ). This analysis showed that methylation of CDH1 and GDNF loci was significantly higher in active inflamed mucosa than in quiescent colon mucosa (p = 0.045 and 0.002, respectively). There were no significant differences in the methylation levels of four other gene loci (ABCB1, ESR1, HPP1, and MYOD1) between active inflamed colon mucosa and quiescent colon mucosa.
Because it has been reported that six genes analyzed in this study are methylated due to various reasons, particularly in an age-dependent manner, [7, 26, 27] we examined whether methylation of CDH1 and GDNF was unequivocally caused by mucosal inflammation via multiple linear regression analysis. Six parameters including age, gender, disease duration, total amount of corticosteroids, clinical course (steroid-dependence or -refractory), and inflammatory status (active or quiescent) were used for the analysis ( Table 2 ). The results indicated that active inflammation was an independent factor for methylation of both CDH1 and GDNF loci (p = 0.02 and 0.0006, respectively). In addition, disease duration and total amount of steroids were significant factors for methylation of GDNF (p = 0.02 and 0.01, respectively). Although a similar analysis was performed for both patient groups with a large overall increase in methylation and with a small overall increase in methylation, no other significant factors were identified. These results suggest that there are gene loci that are specifically methylated by active mucosal inflammation caused by UC.
Immunohistochemistry of DNA methyltransferases
Because we found that methylation specifically occurred in inflamed mucosa of 
Discussion
The data presented here demonstrate that methylation levels of several gene-associated CpG islands were substantially higher in active inflamed colon mucosa than in quiescent colon mucosa in UC patients. Particularly, CDH1 and GDNF loci were significantly more highly methylated in active colon mucosa. Finally, increased methylation in inflamed UC may result from the upregulation of DNMT1 expression.
The phenomenon that methylation in colon mucosa of UC is correlated with active inflammation supports the observations associated with natural history of UC. In contrast to mutation, methylation is prevalent in nonneoplastic cells and is reversible. In fact, methylation in gastric nonneoplastic mucosa caused by H.pylori can be reversed by eradication of the bacteria. [5] In UC, appropriate medication can allow recovery of actively inflamed mucosa into quiescent mucosa. In addition, the mucosal inflammatory status of different colonic locations at different times can vary in UC patients. Thus, these disease properties of UC may be correlated with the reversible character of DNA methylation.
Although there have been studies reporting increased DNA methylation in colonic mucosa of UC, the majority correlated methylation with the occurrence of UC-related dysplasia/cancer without considering the mucosal inflammatory status. was present in the normal-appearing epithelium from UC patients with high-grade dysplasia or cancer. [7] Tominaga et al. [8] analyzed ESR1 methylation in different parts of the large intestine in UC patients with and without neoplasia and proved that ESR1 methylation was correlated with an increased risk of developing neoplasia. These reports suggest that the methylation levels of colonic mucosa of UC vary according to the presence or absence of neoplasia and that accumulation of methylation finally induces cancer development, as shown in H.pylori related gastritis [11, [32] [33] [34] [35] and termed 'epigenetic field cancerization'. [34] In addition to this evidence, we demonstrate that methylation of colonic mucosa is largely correlated with active inflammation of the mucosa. A clinical study indicated that the severity of microscopic inflammation over time is an independent risk factor for developing advanced colorectal neoplasia among patients with long-standing UC. [36] This clinical feature may be due to the accumulation of methylation caused by active inflammation, culminating as epigenetic field cancerization of UC.
We selected 15 candidate gene loci and found methylation in 6 loci in colonic mucosa of UC patients. Expression of ABCB1 in the intestinal tract has an important role in the pharmacokinetics of drugs used to treat UC, such as corticosteroids, and methylation of this locus was reported in colonic mucosa of UC. [21] E-cadherin is encoded by the CDH1 gene, which is located on chromosome 16q22. Azarschab et al.
found methylation of CDH1 to be associated with dysplasia of UC. [22] Issa et al. [7] reported that ESR1 and MYOD1, which are affected by age-related methylation in colorectal epithelium, were extensively methylated not just in the neoplastic mucosa but also in the normal-appearing epithelium from UC patients with high-grade dysplasia or cancer. Methylation of HPP1, found by screening hyperplastic polyps and normal mucosa, was shown to be a relatively common early event in UC-associated carcinogenesis. [9] GDNF expression is up-regulated in inflammatory bowel disease and experimental colitis, and this neurotrophic factor has strong anti-apoptotic effects on colonic epithelial cells. [23] Methylation of GDNF was observed in a subset of colorectal cancer. [16] These loci were methylated to some extent in colon mucosa of UC, whereas the other 9 loci (APEX, CDKN2A, CLDN1, CTNNB1, DDB1, MLH1, MGMT, and SOCS1, SMAD2) were not methylated. The results suggest that methylation caused by inflammation of UC is locus specific, although the mechanism is unknown.
However, such locus specific methylation has also been reported in H. pylori-related gastric inflammation. [11, 35] Our results indicate that active inflammation was the strongest determinant for the PMRs of both CDH1 and GDNF. E-cadherin (encoded by CDH1) mediates cell-cell adhesion in colon epithelium. A previous report observed a substantial decrease in membranous E-cadherin expression, with a concomitant increase in cytoplasmic E-cadherin expression, in UC-related cancer. [37] The decrease in membranous E-cadherin may be an early event in UC-related tumorigenesis because decreased membranous E-cadherin expression can also be detected in UC-affected, nondysplastic colonic mucosa. [38] In addition, a previous study showed that CDH1 promoter methylation might be involved in neoplastic progression from chronic inflammation to colorectal cancer in patients with long-standing UC. [22] Taken together, methylation of CDH1 correlates with active inflammation of colonic mucosa and may be correlated with a decrease in membranous E-cadherin. As a result, accumulation of methylation at this locus may be involved in UC-related carcinogenesis.
On the other hand, GDNF family ligands and their receptors activate the Ret signaling pathway and regulate cell survival and proliferation. [39] In addition, Ret expression compromises neuronal cell survival in the colon. [40] Therefore, it has been considered that GDNF is a novel member in the set of protective mucosal factors. [23] In this context, dysregulation of GDNF can lead to down-regulation of Ret expression and may finally result in failure of colonic mucosal protection. Thus, methylation of the GDNF locus may itself be correlated with severe inflammation in colon mucosa of UC through loss of mucosal protection. Moreover, neoplastic progression may be facilitated by the loss of mucosal protection involving GDNF.
The deregulation of DNMT expression (mainly DNMT1 and DNMT3b) has been shown to contribute to tumorigenesis and tumor suppressor gene hypermethylation [41] . In conclusion, we showed that there are loci methylated in accordance with mucosal inflammation in colonic mucosa of UC patients. In particular, increased methylation of CDH1 and GDNF is specific to mucosal active inflammation. Our results may indicate a potential epigenetic mechanism underlying mucosal inflammation and occurrence of dysplasia/cancer with chronic inflammation in UC patients.
Figure Legends
Figure 1
The differences in methylation levels between the quiescent proximal and active distal colon mucosa of each UC patient. (n = 21)
Wilcoxon signed-ranks test Figure 2 The differences in methylation levels between active proximal and active distal colon mucosa of each UC patient. (n = 13)
Wilcoxon signed-ranks test Figure 3 The differences in methylation levels between the quiescent (n=21) and active (n=41) colon mucosa from all examined UC patients. Mann-Whitney's U test Figure 4 Immunohistochemical staining of DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a) and DNA methyltransferase 3b (DNMT3b). DNMT1 expression was strong in active inflamed mucosa of UC patients (A), weak in quiescent mucosa of UC (D), and weak in normal appearing mucosa from a colorectal cancer patient (G). DNMT3b showed an expression pattern similar to that of DNMT1, although the intensity of DNMT3b in active inflamed mucosa was slightly weaker than that of DNMT1 (C, F, and I). DNMT3a was negative in active inflamed mucosa of UC, quiescent mucosa of UC, and normal appearing mucosa from a colorectal cancer patient (B, E, and H). Magnification of each figure was ×200. The scale bars indicate 100 μm.
